Compare AU
Compare CURE vs. GOOD
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are CURE and GOOD. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
CURE | GOOD | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 78 | 1 |
Median incremental investment | $640.11 | $643.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,274.70 | $649.22 |
Average age group | > 35 | > 35 |
Key Summary
CURE | GOOD | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 27.78m in AUM and 125 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | GOOD.AX was created on 2023-02-07 by Janus Henderson. The fund's investment portfolio concentrates primarily on broad credit fixed income. The Fund seeks to achieve a total return before fees that exceeds the total return of the Benchmark by 0.75% p.a. over rolling 3 year periods. |
Top 3 holdings | Natera Inc (2.70 %) Vertex Pharmaceuticals Inc (2.67 %) Alnylam Pharmaceuticals Inc (2.64 %) | Janus Henderson Sustainable Credit Active ETF (100 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.45 % | 0.5 % |
Key Summary
CURE | GOOD | |
|---|---|---|
Issuer | Global X | Janus Henderson |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.5 % |
Price | $42.49 | $51.22 |
Size | $28.786 million | N/A |
10Y return | N/A | N/A |
Annual distribution/ dividend yield (5Y) | 4.24 % | 1.73 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 14/03/2023 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | GOOD | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 78 | 1 |
Median incremental investment | $640.11 | $643.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,274.70 | $649.22 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | GOOD | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | GOOD |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |